Taxotere, Docetaxel Newswire (Page 6)

Taxotere, Docetaxel Newswire (Page 6)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 6)

Results 101 - 120 of 1,316 in Taxotere, Docetaxel (generic)

  1. American Society for Radiation Oncology Release: Aggressively...Read the original story

    Sep 25, 2017 | BioSpace

    Patients in the phase II clinical trial received half the standard radiation dose but achieved equally high cure rates at two years following treatment. Standard treatment for oropharyngeal squamous cell carcinoma can include surgery to remove the cancer followed by radiation therapy with or without chemotherapy.

    Comment?

  2. Eagle Pharmaceuticals (EGRX) and Its Rivals Critical AnalysisRead the original story w/Photo

    Sep 25, 2017 | The Breeze

    Eagle Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it contrast to its rivals? We will compare Eagle Pharmaceuticals to similar companies based on the strength of its earnings, institutional ownership, dividends, profitability, valuation, analyst recommendations and risk. Eagle Pharmaceuticals currently has a consensus target price of $72.50, suggesting a potential upside of 25.82%.

    Comment?

  3. Adding radiation to chemotherapy may dramatically improve survival for advanced NSCLCRead the original story w/Photo

    Sep 25, 2017 | PhysOrg Weblog

    Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology . Progression-free survival in the trial escalated from 3.5 months to 9.7 months with the addition of radiation therapy delivered to all the metastatic sites of lung cancer as well as the primary disease site.

    Comment?

  4. American Society For Radiation Oncology Release: Adding Radiation...Read the original story

    Sep 24, 2017 | BioSpace

    Progression-free survival in the trial escalated from 3.5 months to 9.7 months with the addition of radiation therapy delivered to all the metastatic sites of lung cancer as well as the primary disease site. Treatment-related side effects were similar for the two treatment approaches.

    Comment?

  5. Aggressively Reduced Radiation Therapy for HPV-Related Throat Cancer...Read the original story w/Photo

    Sep 24, 2017 | Newswise

    SAN DIEGO, September 25, 2017 For certain patients with oropharyngeal cancer caused by the human papilloma virus , an aggressive reduction of radiation therapy after surgery may provide excellent cancer control while simultaneously reducing post-treatment side effects, improving quality of life and lowering treatment costs, according to research presented today at the 59th Annual Meeting of the American Society for Radiation Oncology . Patients in the phase II clinical trial received half the standard radiation dose but achieved equally high cure rates at two years following treatment.

    Comment?

  6. Eagle Pharmaceuticals (EGRX) versus Its Rivals Head-To-Head SurveyRead the original story w/Photo

    Sep 24, 2017 | IntersportsWire

    Eagle Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it contrast to its peers? We will compare Eagle Pharmaceuticals to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, analyst recommendations, valuation and dividends. 66.4% of shares of all "Specialty & Advanced Pharmaceuticals" companies are owned by institutional investors.

    Comment?

  7. Adding Radiation to Chemotherapy May Dramatically Improve Survival for Advanced-Stage NSCLC PatientsRead the original story w/Photo

    Sep 24, 2017 | Newswise

    SAN DIEGO, September 24, 2017 Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology . Progression-free survival in the trial escalated from 3.5 months to 9.7 months with the addition of radiation therapy delivered to all the metastatic sites of lung cancer as well as the primary disease site.

    Comment?

  8. Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific...Read the original story

    Sep 22, 2017 | PressReleasePoint

    Roche receives EU approval of TECENTRIQ in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer TECENTRIQ is a new treatment option for people with metastatic urothelial carcinoma who have been previously treated with a platinum-based chemotherapy and for people who are ineligible to receive cisplatin chemotherapy Roche today announced that the European Commission has granted a marketing authorisation for TECENTRIQ as a monotherapy for the treatment of people with locally advanced or metastatic non-small cell lung cancer after they have been previously treated with chemotherapy regardless of PD-L1 status.

    Comment?

  9. Starpharma Release: DEP Docetaxel Positive Phase I Results; Phase II CommencesRead the original story

    Sep 21, 2017 | BioSpace

    The trial has now been adapted to transition seamlessly into phase 2, with ethics and regulatory approvals already granted, and recruitment and patient screening activities underway for this next phase. The phase 1 trial enrolled 27 patients with advanced solid cancers, including lung , prostate, pancreatic, gastro-oesophageal, breast, cervical, renal and brain.

    Comment?

  10. North America Lung Cancer Therapeutics Market to reach $2.44 billion by 2021Read the original story

    Sep 21, 2017 | Emailwire.com

    The North America Lung Cancer Therapeutics Market was worth $1.81 billion in 2016 and estimated to be growing at a CAGR of 6.14%, to reach $2.44 billion by 2021. North America led the overall market in 2016 and was closely followed by Asia Pacific.

    Comment?

  11. Eagle Pharmaceuticals (EGRX) and Its Peers Head to Head SurveyRead the original story w/Photo

    Sep 21, 2017 | IntersportsWire

    Eagle Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it contrast to its rivals? We will compare Eagle Pharmaceuticals to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, profitability, earnings and analyst recommendations. Eagle Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.

    Comment?

  12. Analyzing Eagle PharmaceuticalsRead the original story w/Photo

    Sep 20, 2017 | Daily Political

    Eagle Pharmaceuticals and AbbVie are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends. This is a breakdown of recent ratings and price targets for Eagle Pharmaceuticals and AbbVie, as reported by MarketBeat.com.

    Comment?

  13. Head-To-Head Comparison: Eagle PharmaceuticalsRead the original story w/Photo

    Sep 19, 2017 | The Breeze

    Eagle Pharmaceuticals and Aimmune Therapeutics are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. 72.9% of Aimmune Therapeutics shares are held by institutional investors.

    Comment?

  14. Financial Comparison: Eagle PharmaceuticalsRead the original story w/Photo

    Sep 19, 2017 | AmericanBankingNews.com

    Eagle Pharmaceuticals and TherapeuticsMD are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. This is a breakdown of current ratings and price targets for Eagle Pharmaceuticals and TherapeuticsMD, as reported by MarketBeat.com.

    Comment?

  15. Eagle Pharmaceuticals (EGRX) and TherapeuticsMD (TXMD) Head-To-Head SurveyRead the original story w/Photo

    Sep 19, 2017 | Daily Political

    Eagle Pharmaceuticals and TherapeuticsMD are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership. Eagle Pharmaceuticals currently has a consensus price target of $72.50, suggesting a potential upside of 25.52%.

    Comment?

  16. Contrasting Aimmune TherapeuticsRead the original story w/Photo

    Sep 19, 2017 | Daily Political

    Aimmune Therapeutics and Eagle Pharmaceuticals are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability. Eagle Pharmaceuticals has higher revenue and earnings than Aimmune Therapeutics.

    Comment?

  17. Head-To-Head Analysis: Eagle PharmaceuticalsRead the original story w/Photo

    Sep 18, 2017 | AmericanBankingNews.com

    Eagle Pharmaceuticals and AbbVie are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability. Eagle Pharmaceuticals has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.

    Comment?

  18. Eagle Pharmaceuticals (EGRX) and Its Competitors Financial ReviewRead the original story w/Photo

    Sep 18, 2017 | AmericanBankingNews.com

    Eagle Pharmaceuticals is one of 19 publicly-traded companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it compare to its rivals? We will compare Eagle Pharmaceuticals to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends. 66.4% of shares of all "Specialty & Advanced Pharmaceuticals" companies are owned by institutional investors.

    Comment?

  19. Critical Analysis: Eagle PharmaceuticalsRead the original story w/Photo

    Sep 18, 2017 | AmericanBankingNews.com

    Eagle Pharmaceuticals and AbbVie are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends. AbbVie pays an annual dividend of $2.56 per share and has a dividend yield of 2.9%.

    Comment?

  20. Hair growth after chemo: When does hair grow back?Read the original story w/Photo

    Sep 18, 2017 | Medical News Today

    For some people who have undergone treatment for cancer, the regrowth of their hair after chemotherapy is a visible and a heartening sign. Chemotherapy can destroy cancer cells, but it kills healthy cells, too.

    Comment?